Clinical proteomics: challenges, and future perspectives

Date: Thursday, March 1st, 2012
Time: 12:30 pm
Place: H5.38, Royal Victoria Hospital

Presenter: Dr. Joan Gannon (Postdoctoral Fellow, Nilsson Lab)
Discussant: Dr. Josip Blonder (Group leader, Clinical Proteomics, NCI, USA)
Lunch sponsored by: Novartis Pharmaceuticals Canada Inc.

Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
Peter Kamper, Maja Ludvigsen, Knud Bendix, Stephen Hamilton-Dutoit, Gabriel A. Rabinovich, Michael Boe Møller, Jens R. Nyengaard, Bent Honore and Francesco d’Amore

A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease
Terri A Addona1, Xu Shi1,7, Hasmik Keshishian1,7, D R Mani1, Michael Burgess1, Michael A Gillette1,3, Karl R Clauser1, Dongxiao Shen2, Gregory D Lewis2,4,5, Laurie A Farrell2, Michael A Fifer2, Marc S Sabatine2,5,6, Robert E Gerszten1,5,6 & Steven A Carr1